Interferon free hepatitis C treatment regimens: The beginning of another era

被引：7
作者：
Fred Poordad
Grace M. Chee
机构：
[1] Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA 90048
[2] Hepatology Department, Cedars-Sinai Medical Center, Los Angeles, CA 90048
来源：
Current Gastroenterology Reports | 2012年 / 14卷 / 1期
关键词：
Direct acting antivirals; Hepatitis C; Interferon; Interferon free; Polymerase inhibitor; Protease inhibitor; Ribavirin; SVR;
D O I：
10.1007/s11894-011-0229-1
中图分类号：
学科分类号：
摘要：
Hepatitis C is a virus affecting millions worldwide and is a major health risk. With the potentially severe adverse event profile of the current backbone of therapy, interferon, there is an impetus to discover interferon free treatment regimens. With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：74 / 77
页数：3
相关论文
共 25 条
[1]  
Choo Q.-L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science, 244, 4902, pp. 359-362, (1989)
[2]  
Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J., Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus, Lancet, 352, 9138, pp. 1426-1432, (1998)
[3]  
Mchutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.-H., Cort S., Albrecht J.K., Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C, New England Journal of Medicine, 339, 21, pp. 1485-1492, (1998)
[4]  
Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J., Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus, Lancet, 352, 9138, pp. 1426-1432, (1998)
[5]  
Glue P., Fang J.W., Rouzier-Panis R., Et al., Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data, Clin Pharmacol Ther, 68, 5, pp. 556-567, (2000)
[6]  
Grace M., Youngster S., Gitlin G., Sydor W., Lei X., Westreich L., Jacobs S., Brassard D., Bausch J., Bordens R., Structural and biologic characterization of pegylated recombinant IFN-α2b, Journal of Interferon and Cytokine Research, 21, 12, pp. 1103-1115, (2001)
[7]  
Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.-J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.-X., Modi M.W., Farid A., Berthold W., Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C, Bioconjugate Chemistry, 12, 2, pp. 195-202, (2001)
[8]  
Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M.-H., Albrecht J.K., Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial, Lancet, 358, 9286, pp. 958-965, (2001)
[9]  
Fried M.W., Shiffman M.L., Reddy K.R., Et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med, 347, 13, pp. 975-982, (2002)
[10]  
McHutchison J.G., Lawitz E.J., Shiffman M.L., Et al., Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection, N Eng J Med, 361, pp. 580-593, (2009)
123